The vascular contribution to dementia: World Stroke Organization scientific statement
Open Access
- 6 August 2026
- journal article
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (9) , 1211-1234
Abstract
Background: Alzheimer’s disease (AD) and cerebrovascular pathology are the two most common causes of dementia, frequently co-occurring in older people. Community-based neuropathology studies indicate that vascular disease accounts for approximately one-third of the population-attributable risk of dementia, controlling for other pathologies (including AD). The proportion with vascular disease as co-pathology is likely to be higher (50–70%). The most common vascular substrate is cerebral small vessel disease, which includes small artery fibrosis (arteriolosclerosis), vascular amyloid deposits (cerebral amyloid angiopathy), and monogenic forms of small vessel disease, the commonest being Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Post-stroke cognitive impairment following both ischemic stroke and intracerebral hemorrhage also contributes. Aims and Methods: In this World Stroke Organization (WSO) scientific statement, we assembled a multi-disciplinary international group of experts to review the vascular contribution to dementia, encompassing both vascular and neurodegenerative dementia. This statement has been reviewed and approved by the WSO executive. Results: We summarize the epidemiology, neuropathology, cognitive profile, clinical impact and management of vascular disease in dementia and discuss the recent VasCog-2-WSO diagnostic criteria. We consider the substantial overlap with clinical stroke and with AD dementia. We catalog transcriptomic and proteomic studies that have revealed novel candidate molecules ( COL4A1/4A2, HTRA1, TRIM47, FOXF2 ) as possible treatment targets. We appraise imaging-based biomarkers relevant to vascular disease and potential biochemical markers (vascular endothelial growth factor-A, placental growth factor, interleukin-6, matrix metalloproteinase-9, cathepsin-B). We highlight the potential for vascular interventions to treat not only vascular dementia but also the vascular component of neurodegenerative dementia. We review recent clinical trials targeting multiple pathways, including nitric oxide signaling, high blood pressure, the GABAergic system, angiogenic activity, microglial inhibition, PDE3 and PDE5 inhibition, as well as dietary supplementation with omega-3 fatty acids, s-equol and vitamin E. Finally, we consider upcoming opportunities and challenges relevant to vascular disease in dementia. Conclusion: The vascular contribution to dementia is i) substantial, ii) increasingly understood at molecular and mechanistic levels, iii) a source of potential treatment opportunities. Data Access Statement: no original data are presented in this document.Keywords
Funding Information
- Stroke Association (SCLfMP25\100006)
- Health and Social Care Delivery Research Programme (NIHR204290)
- Medical Research Council (MR/R005567/1)
- Medical Research Council (MR/T001402/1)
- Medical Research Council (MR/T033371/1)
- Medical Research Council (UKDRI4002)
- Medical Research Council (UKRI2619)
- Alzheimer's Drug Discovery Foundation (20140901)
- British Heart Foundation (PG/20/10397)
- British Heart Foundation (SP/F/22/150042)
- National Institutes of Health (P30AG086403)
- Japan Agency for Medical Research and Development (JP22ek0109516)
- ZonMw (10510032120003)
- Agence Nationale de la Recherche (ANR-18-RHUS-0002)
- Alzheimer's Association (ADSF-24-1345198-C)
This publication has 214 references indexed in Scilit:
- Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive FunctionJAMA, 2025
- Genetic Complexities of Cerebral Small Vessel Disease, Blood Pressure, and DementiaJAMA Network Open, 2024
- Efficacy and Safety of Cilostazol in Mild Cognitive ImpairmentJAMA Network Open, 2023
- Association of Multimorbidity, Disease Clusters, and Modification by Genetic Factors With Risk of DementiaJAMA Network Open, 2022
- Variation in Population Attributable Fraction of Dementia Associated With Potentially Modifiable Risk Factors by Race and Ethnicity in the USJAMA Network Open, 2022
- Association of Blood Pressure Lowering With Incident Dementia or Cognitive ImpairmentJAMA, 2020
- Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter LesionsJAMA, 2019
- Effect of Intensive vs Standard Blood Pressure Control on Probable DementiaJAMA, 2019
- Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid DepositionJAMA, 2017
- The Prevention of Dementia With Antihypertensive TreatmentNew Evidence From the Systolic Hypertension in Europe (Syst-Eur) StudyArchives of internal medicine (1960), 2002